Anti-serum albumin binding variants
The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
1. An anti-serum albumin immunoglobulin single variable domain comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 412 (DOM7h-14-10 R108C).
2. A multispecific ligand comprising an anti-serum albumin immunoglobulin single variable domain of claim 1 , and a binding moiety that specifically binds a target antigen other than serum albumin.
3. The anti-serum albumin immunoglobulin single variable domain of claim 1 , wherein the variable domain is conjugated to an NCE drug.
4. A fusion protein comprising a polypeptide or peptide drug fused to an anti-serum albumin immunoglobulin single variable domain according to claim 1 .
5. The fusion protein according to claim 4 , wherein the fusion protein comprises a linker between the anti-serum albumin immunoglobulin single variable domain and the polypeptide or peptide drug.
6. The fusion protein according to claim 5 , wherein the linker comprises the amino acid sequence TVA between the anti-serum albumin immunoglobulin single variable domain and the polypeptide or peptide drug.
7. The fusion protein according to claim 5 , wherein the linker comprises the amino acid sequence TVAAPS (SEQ ID NO: 421) between the anti-serum albumin immunoglobulin single variable domain and the polypeptide or peptide drug.
8. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 1 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.
9. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 2 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.
10. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 3 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.
11. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 4 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.
12. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 5 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.
13. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 6 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.
14. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 7 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.
15. An anti-serum albumin immunoglobulin single variable domain comprising comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 2 (DOM7h-14-18), SEQ ID NO: 3 (DOM7h-14-19), SEQ ID NO: 4 (DOM7h-14-28), and SEQ ID NO: 5 (DOM7h-14-36).
16. A multispecific ligand comprising an anti-serum albumin immunoglobulin single variable domain of claim 15 , and a binding moiety that specifically binds a target antigen other than serum albumin.
17. The anti-serum albumin immunoglobulin single variable domain of claim 16 , wherein the variable domain is conjugated to an NCE drug.
18. A fusion protein comprising a polypeptide or peptide drug fused to an anti-serum albumin immunoglobulin single variable domain according to claim 16 .
19. The fusion protein according to claim 18 , wherein the fusion protein comprises a linker between the anti-serum albumin immunoglobulin single variable domain and the polypeptide or peptide drug.
20. The fusion protein according to claim 19 , wherein the linker comprises the amino acid sequence TVA between the anti-serum albumin immunoglobulin single variable domain and the polypeptide or peptide drug.
21. The fusion protein according to claim 19 , wherein the linker comprises the amino acid sequence TVAAPS (SEQ ID NO: 421) between the anti-serum albumin immunoglobulin single variable domain and the polypeptide or peptide drug.
22. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 15 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.
23. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 16 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.
24. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 17 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.
25. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 18 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.
26. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 19 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.
27. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 20 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.
28. A composition comprising the anti-serum albumin immunoglobulin single variable domain of claim 21 , and a pharmaceutically acceptable diluent, carrier, excipient or vehicle.